[Hepatitis C in Egypt, a iatrogenic epidemic].
Vrolijk
J M
JM
Schalm
S W
SW
D000998:Antiviral Agents / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004534:Egypt / Q000453:epidemiology; D006034:Glycyrrhetinic Acid / Q000494:pharmacology / Q000627:therapeutic use; D016174:Hepacivirus / Q000187:drug effects* / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics / Q000201:enzymology / Q000453:epidemiology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000191:economics; D008111:Liver Function Tests; D010936:Plant Extracts / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000191:economics
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010936:Plant Extracts; D011994:Recombinant Proteins; D012254:Ribavirin; D006034:Glycyrrhetinic Acid